Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial

John B. Kostis, Stuart Cobbe, Colin Johnston, Ian Ford, Michael Murphy, Michael A. Weber, Henry R. Black, Pierre Francois Plouin, Daniel Levy, Guiseppe Mancia, Pierre Larochelle, Rainer E. Kolloch, Michael Alderman, Luis Miguel Ruilope, Björn Dahlöf, John M. Flack, Robert Wolf

Research output: Contribution to journalArticlepeer-review


The Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial is a large clinical trial of omapatrilat, a vasopeptidase inhibitor, in patients with stage 1 isolated systolic hypertension (ISH). OPERA is the first study to examine whether effective antihypertensive treatment can provide survival and clinical end point benefits in older persons with this common condition. This 5-year multinational, randomized, double-blind, parallel-group, placebo-controlled, forced-titration study will be conducted in approximately 12,600 subjects randomized by approximately 1100 study centers worldwide over a recruitment period of approximately 2 years. The primary objective of OPERA is to determine whether treatment with once-daily omapatrilat (target dose 40 mg) will reduce cardiovascular (CV) morbidity and mortality in older (≥65 years) men and women with enhanced risk for atherosclerotic events due to stage 1 ISH plus other risk factors for which currently there is no evidence-based requirement for treatment. Blood pressure inclusion criteria are systolic blood pressure (SBP) 140 to 159 mm Hg (SBP 125 to 139 mm Hg in diabetic individuals) and diastolic blood pressure (DBP)

Original languageEnglish
Pages (from-to)193-198
Number of pages6
JournalAmerican Journal of Hypertension
Issue number2 I
Publication statusPublished - 2002


  • Cardiovascular morbidity and mortality
  • Isolated systolic hypertension
  • Omapatrilat

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Design of the omapatrilat in persons with enhanced risk of atherosclerotic events (opera) trial'. Together they form a unique fingerprint.

Cite this